Pharmacogenetics in cardiovascular antithrombotic therapy.

@article{Marin2005PharmacogeneticsIC,
  title={Pharmacogenetics in cardiovascular antithrombotic therapy.},
  author={Franc{\'i}sco Marin and Vanessa Rold{\'a}n and Roc{\'i}o Gonz{\'a}lez-Conejero and Javier Corral},
  journal={Current medicinal chemistry. Cardiovascular and hematological agents},
  year={2005},
  volume={3 4},
  pages={
          357-64
        }
}
Thrombosis is the most important underlying mechanism of coronary heart disease and embolic stroke. Therefore, antithrombotic therapy is commonly used in cardiovascular diseases. Unfortunately, the benefits are limited, and an important proportion of treated patients will suffer a new thrombotic event. Lack of clinical benefits may be related to heterogeneous response to antithrombotic treatment among individuals (inter-individual heterogeneity). Few factors have been identified to be involved… CONTINUE READING

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 161 REFERENCES

Ticlopidine and clopidogrel.

VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Haemostatic gene polymorphisms in venous and arterial thrombosis.

  • Pathophysiology of haemostasis and thrombosis
  • 2002
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Contribution of gene sequence variations of the hepatic cytochrome P 450 3 A 4 enzyme to variability in individual responsiveness to clopidogrel

DJ Angiolillo, A Fernández-Ortiz, E Bernardo
  • Arterioscler Thromb Vasc Biol
  • 2007